FY26-27 Pediatric Covid-19 Vaccines

Solicitation / RFP / RFQ

This document is a solicitation for commercial items, identified by Solicitation Number 75D301-26-R-73403. The issuing agency is the Centers for Disease Control and Prevention (CDC), Office of Acquisition Services.

Details regarding the specific supplies or services are to be found in the "Schedule of Supplies/Services" and "See Schedule" sections, indicating that a detailed schedule is attached or referenced.

• Solicitation Issue Date: 03/04/2026

• Award/Effective Date: 06/01/2026

• The contract is a "Rated Order" under DPAS (15 CFR 700).

• Offer Due Date/Local Time: 03/17/2026 at 1:00 PM EDT.

• Method of Solicitation: RFP (Request for Proposal).

• FAR clauses 52.212-1, 52.212-3, and 52.212-4 are incorporated by reference, with 52.212-5 and any addenda attached.

• Contractors are required to sign and return one copy of the document.

This acquisition is marked as "Unrestricted."

• The NAICS code is 325412 with a Size Standard.
• Payment will be made by the Center of Disease Control (CDC), Office of Financial Resources.
• Invoices should be submitted to the address shown in Block 18a unless otherwise indicated.
• Standard Form 1449 is used for this solicitation.

Solicitation / RFP / RFQ

This solicitation is for the procurement of pediatric COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) intends to award one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to manufacturers of pediatric vaccines. The goal is to ensure the availability of vaccines for the Vaccine for Children (VFC) program and Section 317 vaccine purchase funds, potentially at prices below the commercial market. The government also requires the ability to purchase vaccines for the 2025-2026 season in addition to the primary 2026-2027 season.

• Offeror Eligibility: Must be a manufacturer of pediatric vaccines as defined by 42 U.S.C. § 1396s.

• Product: Pediatric COVID-19 vaccines for individuals aged 18 years and younger.

• Contract Type: Firm-Fixed-Price Indefinite Delivery/Indefinite Quantity (ID/IQ).

• Period of Performance: 06/01/2026 – 05/31/2027.

• Delivery: Within 15 working days after receipt of order.

• Shelf Life: Minimum 12 months remaining upon delivery.

• Packaging: Standard commercial packaging, maintaining FDA recommended temperatures during transit. Electronic temperature monitoring required.

• Compliance: Must adhere to Current Good Manufacturing Practice Regulations (CGMPRs).

• Ordering: Orders will be placed via the Vaccine Tracking System (VTrckS).

• Maximum Value: Combined maximum value for all contracts is $1,648,962,000.00.

• Proposal Submission Deadline: March 17, 2026, 1:00 PM EST.

• Questions Deadline: March 10, 2026, 1:00 PM EST.

• Submission Method: Electronically via email to specified CDC contacts.

• Evaluation Factors: Technical Proposal (meeting specific vaccine requirements, shelf life, licensure, pricing), Price Proposal (unit price including FET), and Past Performance.

• Offerors must be manufacturers of pediatric vaccines.

• Small business subcontracting plans are required for non-small business offerors.

• The solicitation references Standard Form 1449, contract clauses, and solicitation provisions.

• Specific details regarding vaccine presentations, quantities, and pricing for the 2025-2026 and 2026-2027 seasons are required.

• Offerors must be able to interface with the CDC electronic vaccine ordering system (VTrckS).

Solicitation / RFP / RFQ

This document is a solicitation for commercial items, identified by Solicitation Number 75D301-26-R-73405. The issuing agency is the Centers for Disease Control and Prevention (CDC), Office of Acquisition Services.

Details regarding the specific supplies or services required are to be found in the "Schedule of Supplies/Services" section, which is referenced as "See Schedule."

• Solicitation Issue Date: 03/04/2026

• Award/Effective Date: 06/01/2026

• Offer Due Date/Local Time: 03/17/2026, 1:00 PM EDT

• Method of Solicitation: RFP (Request for Proposal)

• NAICS Code: 325412

• Size Standard: Not specified, but likely related to the NAICS code.

• Offerors are instructed to complete blocks 12, 17, 23, 24, and 30.

• Invoices are to be submitted to the address shown in Block 18a unless otherwise indicated.

• The solicitation incorporates by reference FAR 52.212-1, 52.212-4, and 52.212-5. These clauses, along with any addenda, are attached.

• Contractors are required to sign the document and return one copy to the issuing office.

This acquisition is marked as "Unrestricted." There is no specific set-aside indicated.

• The document is 32 pages long.
• The "Schedule of Supplies/Services" is not detailed on this cover page and must be referenced separately.
• Standard Form 1449 is used for this solicitation.

Solicitation / RFP / RFQ

This solicitation is for the procurement of standard commercial adult COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) intends to award one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to provide vaccines for the 2025-2026 and 2026-2027 seasons. The goal is to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below the commercial marketplace for distribution to state and local health departments to support adult immunization programs.

• Product: Standard commercial adult COVID-19 vaccines (age 19 years and older).

• Quantity: Minimum order size of 100 doses; maximum of 10 million doses per item.

• Seasons: Vaccines for the 2025-2026 and 2026-2027 seasons.

• Shelf Life: Minimum 12 months remaining upon delivery.

• Packaging: Standard commercial manner, maintaining FDA recommended temperatures during transit. Electronic temperature monitoring device required.

• Delivery: Within 15 working days after receipt of order to CDC centralized distribution locations (Olive Branch, MS and Clermont, KY) or specified clinic locations.

• Compliance: Vaccines must be manufactured under current FDA establishment and product license. Adherence to Current Good Manufacturing Practice Regulations (CGMPRs) is required.

• DSCSA Compliance: Shipments must include all transaction information necessary for Drug Supply Chain Security Act compliance.

• VTrckS Interface: Contractors must be able to interface with the CDC electronic vaccine ordering system (VTrckS).

• Contract Type: Indefinite Delivery Indefinite Quantity (ID/IQ) with Firm-Fixed-Price delivery orders.

• Period of Performance: Orders may be issued from 06/01/2026 through 05/31/2027. The contract period of performance is 12 months from the date of award.

• Maximum Contract Value: Combined maximum value for all contracts is $892,363,500.00.

• Pricing: Contract unit prices shall not exceed the manufacturer’s current Federal Ceiling Price (FCP). Federal Excise Tax (FET) is applicable ($0.75 per dose).

• Proposal Submission Deadline: March 17, 2026, 1:00 PM EST.

• Questions Deadline: March 10, 2026, 1:00 PM EST.

• Submission Method: Electronic via email to specified CDC contacts.

• Evaluation Factors: Technical Proposal (meeting vaccine requirements, shelf life, FDA licensure, pricing, VTrckS interface), Price Proposal, and Past Performance.

• Offerors must propose FDA-approved vaccines.

• Subcontracting plans are required for other than small business offerors, submitted via the HHS Small Business Customer Experience (SBCX) system.

• The solicitation references numerous FAR and HHSAR clauses and provisions that bidders must review.

• An Authorized Distributor of Record (ADR) Agreement is required (Section D-1).

Form / Attachment / Pricing Sheet

This document, titled "List of Products," serves as an attachment to the opportunity record. It outlines specific products required by the government.

• Item Number
• Product/Brand Name
• National Drug Code (NDC)

Bidders should use this list to identify the specific products, such as vaccines, that are part of the government's requirement. This information is crucial for accurately preparing product offerings and pricing within their proposals.

Form / Attachment / Pricing Sheet

This document is an Authorized Distributor of Record (ADR) Agreement between a Manufacturer/Supplier and the Centers for Disease Control and Prevention (CDC). It designates the CDC as an ADR in accordance with the Prescription Drug Marketing Act (PDMA) of 1988 and its implementing regulations (21 CFR Part 203).

• The agreement establishes an "ongoing relationship" for the distribution of pharmaceutical products or vaccines.
• The Manufacturer/Supplier must specify whether the CDC is an ADR for their entire product line or for specific products listed on an attachment (D-2).
• If specific products are listed, they must include pharmaceutical/vaccine name, dosage form, strength, and NDC number.
• The agreement is valid until terminated by either party with ninety (90) days written notice.
• It does not alter any other pre-existing or future distribution agreements.
• The agreement confers only the right to designate the CDC as an ADR and is not a sales agreement.

This document is crucial for any bidder whose opportunity involves the CDC acting as an Authorized Distributor of Record. It outlines the legal framework and requirements for this designation, including product identification and the duration of the agreement. Bidders should ensure their opportunity aligns with the terms and conditions of this ADR agreement, particularly regarding the specific products or the entire product line covered.